About Lisa Lewin

This author has not yet filled in any details.
So far Lisa Lewin has created 26 blog entries.

Simon Fleming Joins Precision

2024-02-13T07:37:58-05:00Cell & Gene Therapy, News|

Simon Fleming has joined the Precision leadership team as Executive Vice President, Clinical Solutions. With over 30 years of experience leading global functions at a large CRO, Simon’s invaluable expertise will strengthen Precision across multiple fronts. He brings an impressive track record of performance, technical skills, and passion for aligning teams to drive research forward. We are confident Simon will make immediate strategic contributions as we continue advancing and accelerating the development of life-changing innovations.




Article: Scrip Asks…What Does 2024 Hold For Biopharma? Part 3: Manufacturing And Supply

2024-01-30T08:32:06-05:00Cell & Gene Therapy, Thought Leadership|

Precision’s Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series.

“Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types.” (subscription required):


Article: Connecting Institutions and Global Sites: Q&A With Sofia Baig, President of Clinical Solutions at Precision for Medicine

2024-01-24T17:53:03-05:00Cell & Gene Therapy, Thought Leadership|

As clinical trial protocols have become more complex in recent years, institutions are facing new challenges in keeping up with the advancements. In this Q&A, Precision’s Sofia Baig, President of Clinical Solutions, discusses the challenges these institutions are facing, how sites can keep pace with new technologies, and improving efficiency in early and later phase research.


Article: AAV-based gene therapies hold promise for treating CNS conditions

2024-01-04T09:01:10-05:00Thought Leadership|

Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations. AAV-based therapeutics have been the most successful in vivo gene therapies for patients with central nervous system disorders. Precision’s Deb Phippard identifies challenges to their development with assessing, minimizing and mitigating immunogenicity.


Precision Medicine Group Releases Its Inaugural Environmental, Social and Governance (ESG) Report

2023-12-14T08:40:44-05:00Cell & Gene Therapy, News, Thought Leadership|

Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:

· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues

· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities

· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders

· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes



Article: Generative AI Holds the Key to Transforming Trial Design

2023-12-18T11:38:30-05:00Thought Leadership|

Recent AI applications rely heavily on predictive AI, which harnesses historical data to make predictions and recommendations for the future. But what is really propelling the industry forward is generative AI, which uses models or algorithms to create various types of content using learned patterns based on the data on which it was trained.

SVP/Chief Architect Tobias Guennel outlines how generative AI will speed up clinical trial execution as sponsors integrate AI-enabled technologies into their day-to-day workflows.


Load More Posts